Skip to main content

Skin and nailsGuide

Porokeratosis

Porokeratosis is an uncommon skin condition that forms rough bumps or ring-shaped patches with a raised edge. It tends to last, and no single treatment is established. Sun protection and watching patches for change matter, because a minority can turn into skin cancer.

Reviewed by Andrew Schox, BSc(Hons) PGradDipPod MPodLast reviewed 22 November 2026 6 min read

Jump to a section
  1. 1. What is porokeratosis, and how common is it?
  2. 2. What causes it, and who gets it?
  3. 3. What does it look like, and what can make it serious?
  4. 4. What helps first?
  5. 5. What helps if that isn't enough?
  6. 6. How long does it last, and can it come back?

At a glance

  • It's a skin condition with raised-edge patches. It forms rough bumps or ring-shaped patches, and it comes in several types.
  • Genes play the main part, and sunlight, a weakened immune system and some medical treatments can act as triggers.
  • It tends to last. Most patches persist without treatment, and results from treatment are often incomplete or temporary.
  • A minority of patches can turn into skin cancer, so changes in a patch are worth knowing about.
  • No single treatment is established as the first choice. Options include creams, tablets and treatments that destroy the patch.

What is porokeratosis, and how common is it?

Porokeratosis is an uncommon skin condition. The outer layer of skin builds up too much keratin (the tough protein that makes skin hard), forming rough bumps or ring-shaped patches with a raised edge. It's really a group of related conditions, named by how they look and where they appear. Under a microscope they all share a distinctive column of abnormal cells along the raised edge, called a cornoid lamella.

The most common type is disseminated superficial actinic porokeratosis (DSAP). It usually appears in people in their 30s and 40s, with a slight female predominance, on sun-exposed skin. Other types include linear porokeratosis, punctate porokeratosis and porokeratosis of Mibelli. Porokeratosis ptychotropica is a rare type affecting the genitals, buttock folds and the area around the anus. How common porokeratosis is worldwide isn't known.

What causes it, and who gets it?

Genes play the main part. Changes in genes of the mevalonate pathway (a set of steps inside skin cells) have been found in families where porokeratosis runs, and in people with no family history. A second, later change in the skin cells is thought to be needed before patches appear. Some sources still describe the cause as unclear.

Several things may help patches appear:

  • Sunlight. Porokeratosis is linked with ultraviolet radiation, and it's seen more often in places with a lot of sun. DSAP mainly occurs in sunny countries and worsens after sun exposure.
  • A weakened immune system. Cases have been linked with immunosuppression, particularly in people who've had a solid organ or bone marrow transplant.
  • Inflammation or injury to the skin, which may help the abnormal cells expand.
  • Some medical treatments, such as biologics, phototherapy and radiotherapy. Porokeratosis that appears during these may be drug-related, but the link is possible to probable rather than proven.

What does it look like, and what can make it serious?

A patch usually starts as a small, dry, brownish bump of a few millimetres that doesn't hurt. Over weeks to months it slowly spreads outward into a well-defined patch with a raised, threadlike edge and often a thinner, sunken centre. DSAP typically shows as many small ring-shaped patches (sometimes over 100) of about 1 cm, on both sides of the body, on sun-exposed skin. They may be itchy or have no symptoms. Porokeratosis ptychotropica shows as itchy, wart-like patches on the buttocks, and can be mistaken for psoriasis, warts, chronic intertrigo (a rash in skin folds), lichenified eczema or lichen planus.

The look of a patch gives the first clue. A small skin sample (a biopsy) examined under a microscope shows the cornoid lamella in all types.

The main serious feature is skin cancer. Porokeratosis is considered premalignant, which means a patch can change into squamous cell carcinoma (a skin cancer), or less often Bowen's disease or basal cell carcinoma. Reported rates range from about 7% to 16% depending on the source. The overall outlook is still favourable. Risk differs by type: lower in DSAP and higher in linear porokeratosis. Risk is greatest in large, long-standing, linear, giant or irradiated patches, patches on the hands or feet or limbs, and in people with a lot of sun exposure or a weakened immune system.

Changes in a patch that can mean cancer has developed include:

  • rapid growth or new hardness;
  • a thickened nodule that doesn't go away;
  • ulceration, bleeding without a knock, or crusting;
  • pain, or loss of the regular raised edge;
  • a red, scaly ring that becomes a raised lump.

More generally, skin growths that get bigger, change colour or texture, or hurt, itch, bleed, crust or scab for more than 4 weeks are signs of skin cancer. A biopsy is used to check patches with these changes. When cancer arises in porokeratosis, it can be multiple, and rarely it spreads to lymph nodes and can be fatal. This is why higher-risk patches are monitored regularly.

What helps first?

No treatment has been established as the standard first choice. The options include creams and other topical treatments, tablets, and treatments that destroy the patch. Most of the information on them comes from individual cases rather than controlled trials. A cream combining cholesterol and a statin (a cholesterol-lowering medicine) is an emerging option aimed at the underlying pathway.

For sun-sensitive types such as DSAP, protection from sunlight is advised: avoiding strong sun, wearing protective clothing and using sunscreen.

What helps if that isn't enough?

No proven next step has been identified. The choices are the same broad groups: topical, tablet and destructive treatments, with the cholesterol and statin cream as an emerging option. Retinoids (medicines related to vitamin A, used as creams or tablets for skin disease) have expected side effects that need weighing when treatment is chosen. Responses to treatment are often incomplete or temporary.

For porokeratosis ptychotropica and other types, reviewers conclude that surveillance, and treatment where it's available, appears necessary.

How long does it last, and can it come back?

Porokeratosis is chronic. It doesn't go away on its own, and most patches persist indefinitely without treatment. Treatment results are often incomplete or temporary. The overall outlook is favourable, but a minority of patches turn malignant. Size, how long a patch has been there, being on the hands or feet, and past radiation all raise that risk.

How to stop porokeratosis coming back hasn't been shown. Sun protection is a sensible step, but it hasn't been shown to prevent recurrence or lower cancer rates. Sun-protection advice and regular follow-up to watch for malignant change are recommended, so any change is picked up as early as possible. How often checks should happen isn't clear yet.

Common questions

Is porokeratosis cancer?

No. Porokeratosis itself isn't cancer, but it's considered premalignant, which means some patches can change into skin cancer, most often squamous cell carcinoma. A minority do, and the overall outlook is favourable. Higher-risk patches are monitored regularly so any change is found early.

Does porokeratosis go away on its own?

Not usually. Porokeratosis is chronic and doesn't clear by itself. Most patches persist indefinitely without treatment, and responses to treatment are often incomplete or temporary.

Is porokeratosis hereditary?

It can be. Changes in certain genes have been found both in families with porokeratosis and in people with no family history, so it can run in families but also appears without one. A second change in the skin cells is thought to be needed before patches develop.

Are statin creams used for porokeratosis?

A cream combining cholesterol and a statin (a cholesterol-lowering medicine) is an emerging option aimed at the underlying cause. No treatment has been established as the standard first choice, so it's one of several options described.

Further reading

Want to know more? Porokeratosis on Clindice

Reviewed by Andrew Schox, BSc(Hons) PGradDipPod MPod

Podiatrist

Reviewed 22 November 2026. Next review by 22 November 2027.

How we write and review Learn

Was this page helpful?

Sources

(13)
  1. 1.PorokeratosisPubMed
  2. 2.Efficacy of Topical Cholesterol and Statin Combination Therapy in the Treatment of Porokeratosis: A Systematic Review and Meta-AnalysisCasale F, Walters N, Peach A et al. · Journal of Drugs in Dermatology · 2023
  3. 3.Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapyAtzmony L, Lim YH, Hamilton C et al. · Journal of the American Academy of Dermatology · 2020
  4. 4.Malignant Transformation in Porokeratosis Ptychotropica: A Systematic ReviewLoh CH, Tan CL, Tan KB et al. · Acta Dermato-Venereologica · 2024
  5. 5.PorokeratosisSathe NC, Fillman EP · NCBI Bookshelf · 2024
  6. 6.Porokeratoses: an update on pathogenesis and treatmentKostopoulos-Kanitakis KA, Kanitakis J · International Journal of Dermatology · 2025
  7. 7.Drugs associated with development of porokeratosis: A systematic reviewLu JD, Mufti A, Sachdeva M et al. · Dermatologic Therapy · 2021
  8. 8.Porokeratoses: an update of clinical, aetiopathogenic and therapeutic featuresKanitakis J · European Journal of Dermatology · 2014
  9. 9.PorokeratosisAustralasian College of Dermatologists
  10. 10.Symptoms of non-melanoma skin cancerNHS
  11. 11.A Clinico-Epidemiological Study on PorokeratosisShirahatti T, Bangaru H, Sathish S · Indian Journal of Dermatology · 2024
  12. 12.Topical statins in the treatment of porokeratosis: a systematic reviewMartini J, Buethe MG, Atzmony L · Clinical and Experimental Dermatology · 2026
  13. 13.Use of Topical and Systemic Retinoids in Solid Organ Transplant Recipients: Update and Review of the Current LiteratureHerold M, Good AJ, Nielson CB et al. · Dermatologic Surgery · 2019

This is general information, not advice about your own situation. To discuss your issues, book with one of our podiatrists. In an emergency, call 000.

Searching…